All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TLA-CA-306PZ | Anti-HTLV-1(TAX-11) (LLFGYPVYV) TCR-Like CAR [scFv (T3A4)-BBζ], HLA-A*0201-Restricted | Human | T-Cell leukemia/lymphoma | LLFGYPVYV | HLA-A*0201 | Lentiviral vector | |
TLA-CA-307PZ | Anti-HTLV-1(TAX-11) (LLFGYPVYV) TCR-Like CAR [scFv (T3D4)-BBζ], HLA-A*0201-Restricted | Human | T-Cell leukemia/lymphoma | LLFGYPVYV | HLA-A*0201 | Lentiviral vector | |
TLA-CA-308PZ | Anti-HTLV-1(TAX-11) (LLFGYPVYV) TCR-Like CAR [scFv (T3F2)-BBζ], HLA-A*0201-Restricted | Human | T-Cell leukemia/lymphoma | LLFGYPVYV | HLA-A*0201 | Lentiviral vector | |
TLA-CA-309PZ | Anti-HTLV-1(TAX-11) (LLFGYPVYV) TCR-Like CAR [scFv (T3E3)-BBζ], HLA-A*0201-Restricted | Human | T-Cell leukemia/lymphoma | LLFGYPVYV | HLA-A*0201 | Lentiviral vector | |
TLA-CA-310PZ | Anti-HTLV-1(TAX-11) (LLFGYPVYV) TCR-Like CAR [scFv (T3D3)-BBζ], HLA-A*0201-Restricted | Human | T-Cell leukemia/lymphoma | LLFGYPVYV | HLA-A*0201 | Lentiviral vector | |
TLA-CA-311PZ | Anti-HTLV-1(TAX-11) (LLFGYPVYV) TCR-Like CAR [scFv (T2H9)-BBζ], HLA-A*0201-Restricted | Human | T-Cell leukemia/lymphoma | LLFGYPVYV | HLA-A*0201 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION